Amyris, Inc. (NASDAQ:AMRS) is scheduled to announce its earnings results after the market closes on Thursday, August 10th. Analysts expect the company to announce earnings of ($1.06) per share for the quarter.

Amyris (NASDAQ:AMRS) last posted its earnings results on Monday, May 15th. The biotechnology company reported ($1.95) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.35) by $0.60. The firm had revenue of $13 million during the quarter, compared to analysts’ expectations of $32.30 million. During the same quarter in the previous year, the business earned ($2.55) earnings per share. The business’s revenue for the quarter was up 47.7% on a year-over-year basis. On average, analysts expect Amyris to post $-4.6 EPS for the current fiscal year and $-3.46 EPS for the next fiscal year.

Amyris, Inc. (NASDAQ AMRS) opened at 3.06 on Tuesday. Amyris, Inc. has a 1-year low of $0.21 and a 1-year high of $18.15. The stock’s 50 day moving average price is $3.47 and its 200 day moving average price is $6.14. The stock’s market capitalization is $60.60 million.

A number of equities research analysts recently issued reports on AMRS shares. Zacks Investment Research lowered Amyris from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. ValuEngine lowered Amyris from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Finally, HC Wainwright reissued a “buy” rating and set a $60.00 price target on shares of Amyris in a research note on Tuesday, May 23rd. Two equities research analysts have rated the stock with a sell rating and three have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $31.13.

In other Amyris news, Director Patrick Y. Yang purchased 300,000 shares of the firm’s stock in a transaction that occurred on Friday, May 19th. The stock was purchased at an average cost of $0.29 per share, with a total value of $87,000.00. Following the purchase, the director now owns 153,000 shares of the company’s stock, valued at $44,370. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 11.30% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at

About Amyris

Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.

Earnings History for Amyris (NASDAQ:AMRS)

Receive News & Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related companies with's FREE daily email newsletter.